Stalevo for Parkinson's

August 2003

See FDA information concerning a possible increased cardiovascular risk with Stalevo

 Novartis is now marketing Stalevo for Parkinson's.

It contains both standard-release carbidopa/levodopa (Sinemet, etc)...PLUS entacapone (Comtan).

It's for patients who already take these drugs separately... or for patients who have "wearing-off" on levodopa. Adding entacapone boosts the efficacy of levodopa and helps it last longer.

Get concise, unbiased advice for effective drug therapy, plus CE/CME

Prescriber Insights: APRN includes:

  • Cutting-edge advice about new medications and how they fit into practice
  • Unbiased, evidence-based, 100% free of financial support from the pharma industry written by your peers
  • Side-by-side comparisons of drugs by class or disease state, plus FAQs, pros/cons, and simple recommendations

Already a subscriber? Log in

Volume pricing available. Get a quote